Makeda Semret
- Feb 10, 2021
- 1 min read

Check out updates to COVID-19 management guideline!

Our guideline working group has reviewed latest evidence and recommends therapeutic anticoagulation (instead of prophylactic) for mild and moderate COVID-19. This is based on review of latest evidence from 3 international trials, demonstrating marked benefit (net benefit in terms of organ-support free days, irrespective of D-dimer levels). No benefit (and possible harm) for severe COVID-19. Endorsed by MUHC P&T committee!

Recent Posts

See All

Update in COVID guidelines

The ASP committee updated the COVID guidelines. You will find the following change: -Removal of the pre-exposure prophylaxis guidelines since monoclonal antibodies are no longer easly available. -Clar

Correction in Antifungal prophylaxis for high-risk (immunocompromised)

Correction made for Heart transplant and Lung transplant recipients: both anti-mold AND anti-PJP prophylaxis recommended.

NEW UPDATE: *Change in process for outpatient COVID-19 management*

To MUHC users: Please note that as of Dec 5, 2022, requests for outpatient antiviral management of COVID-19 for HIGH RISK patients should be directed to the ID-AMB (formerly MicroB/Lachine) service ra